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Department of Medicine, Division of General Internal Medicine and Clinical Innovation, New York University School of Medicine, New York, NY, USAAbstractFormerly known as Nantucket fever, babesiosis is increasing in incidence across the Northeastern United States. Because of its emerging
health risk globally, it is important to be aware of its various presenting manifestations. We present the case of a middle-aged man with
haemolytic anaemia from Babesia microti infection.
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E-mail: Ramon.Jacobs@nyumc.orgCase reportA 45-year-old man presented with a 3-week history of wors-
ening dyspnoea on exertion and fatigue, as well as a dry cough
prompting him to present to the emergency department. He
reported experiencing subjective fevers and weight loss. He
reported recent travel to the Midwest United States from New
York City; however, he had not travelled internationally in
several years. At presentation the patient was tachycardic and
afebrile. Initial laboratory results revealed anaemia (haemoglo-
bin 9.3 g/dL), elevated prothrombin time, hyperbilirubinemia
and hepatitis.
The patient was admitted; follow-up laboratory studies
revealed worsening anaemia (haemoglobin 7.2 g/dL) with
elevated reticulocyte count, lactate dehydrogenase and hapto-
globin as well as a negative direct Coombs test. A parasite
smear looking for Plasmodium or Babesia parasites was per-
formed and demonstrated the presence of intraerythrocytic
ring forms (Fig. 1) suggestive of Babesia microti with an overallw Microbe and New Infect 2015; 8: 148–149
2015 New Microbes and New Infections published by Elsevier Ltd on behalf of European Soc
is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lice
p://dx.doi.org/10.1016/j.nmni.2015.10.008low parasite load of 1%. B. microti serologies showed an
immunoglobulin M level greater than 1:320 with an immuno-
globulin G level of 1:128. Serum for babesial DNA was positive.
Investigation for concurrent infection with Ehrlichia chaffeensis,
Anaplasma phagocytophilum and Borrelia burgdorferi was negative.
He was treated with atovaquone and azithromycin, with im-
provements in symptoms and haemolytic anaemia.DiscussionThe intraerythrocytic protozoan species Babesia microti is the
most common cause of human babesiosis in the United States
and is a growing health concern [1]. Although it is mainly
transmitted to humans through the Ixodes scapularis tick, it has
also been reported by the US Food and Drug Administration to
be the most common transfusion-transmitted pathogen [2]. It is
endemic to the Northeast and upper Midwest regions of the
United States [2].
Clinical manifestations of babesiosis range from an asymp-
tomatic infection to fulminant and sometimes fatal disease.
Common symptoms include fatigue, malaise, myalgia, fever andiety of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
FIG. 1. Parasite blood smear demonstrating presence of intra-
erythrocytic ring-form trophozoite (arrow).
NMNI Hot topic 149headache. Common laboratory abnormalities include a haemo-
lytic anaemia, thrombocytopenia and elevated liver enzymes [1,2].
Our patient’s presentation was atypical for babesiosis. He
required hospitalization despite his younger age and immuno-
competent status. Fever is the most common symptom of
babesiosis, with 85% of patients exhibiting a temperature
greater than 38°C [1]. In 2011 the median age for hospitalized
patients was 68 years [1]. Most patients with B. microti in-
fections who require hospitalization are immunocompromised
with malignancy, prior splenectomy or chronic heart, lung or
liver disease [2].
Adeﬁnitive diagnosis of babesiosis ismadeby visualization of the
intraerythrocytic trophozoites or merozoites (with the classic
ﬁndingof aMaltese cross tetrad) on thin blood smearswithGiemsa
or Wright staining, and must be clinically distinguished from Plas-
modium falciparum [2]. Parasitemia on Giemsa-stained thin blood
smears rarely exceeds 5% in immunocompetent hosts. The© 2015 New Microbes and New Infections published by Elsevier Ltd on behalf
This is an open access artiparasite level and the severity of the disease do not necessarily
coincide [2,3].
Treatment of babesiosis in the immunocompetent patient
with mild to moderate disease typically involves a combination
of atovaquone and azithromycin for 7 to 10 days [4]. Symptoms
typically resolve within a day or two of initiating therapy, and
complete clearance of the infection occurs within 3 months.
Immunocompromised patients with severe disease may require
partial or complete erythrocyte exchange transfusion [2,5].
These patients may experience parasitemia for extended pe-
riods of time [2].
With babesial infections becoming more prevalent across
America, it is important to be able to recognize all spectrums of
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